KELSEY JAMES MOODY, Ph.D., MBA
Dr. Moody is a process-oriented drug developer and executive who has specialized in the study of aging and aging mechanisms for over a decade. Since 2013, Dr. Moody has successfully built Ichor Therapeutics from a living room start-up into a premier, vertically integrated research organization focused on drug discovery and development for pathways of aging. R&D initiatives that constitute Ichor's portfolio companies span enzyme therapy (Lysoclear, Inc.), senolytics (FoxBio, Inc.), small molecule drug discovery (Antoxerene, Inc.), antibody mimetics (Auctus Biologics, Inc.), protein chemistry tools (RecombiPure, Inc.), contract research services (Icaria Life Sciences, Inc.) and a strategic investment fund (Grapeseed.Bio). His work has been published in high impact peer-reviewed journals, including Cell. Dr. Moody holds a PhD in biochemistry and molecular biology from the University of Miami Miller School of Medicine, an MBA in risk management from Concordia University Wisconsin, and a BSc in biochemistry from SUNY Plattsburgh. Dr. Moody also attended medical school at SUNY Upstate while starting Ichor but withdrew after his second year to build the company full-time after raising over $1 million in funding.